Cardiff Oncology, Inc.Cardiff Oncology, Inc.Cardiff Oncology, Inc.

Cardiff Oncology, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪110.47 M‬USD
−0.90USD
‪−41.44 M‬USD
‪488.00 K‬USD
‪41.11 M‬
Beta (1Y)
1.51

About Cardiff Oncology, Inc.

CEO
Mark Erlander
Headquarters
San Diego
Employees (FY)
32
Founded
1999
FIGI
BBG000PXLKM7
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CRDF is 2.51 USD — it has increased by 1.62% in the past 24 hours. Watch Cardiff Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cardiff Oncology, Inc. stocks are traded under the ticker CRDF.
CRDF stock has risen by 11.56% compared to the previous week, the month change is a 16.61% fall, over the last year Cardiff Oncology, Inc. has showed a 79.29% increase.
We've gathered analysts' opinions on Cardiff Oncology, Inc. future price: according to them, CRDF price has a max estimate of 14.00 USD and a min estimate of 7.00 USD. Watch CRDF chart and read a more detailed Cardiff Oncology, Inc. stock forecast: see what analysts think of Cardiff Oncology, Inc. and suggest that you do with its stocks.
CRDF reached its all-time high on Jun 10, 2005 with the price of 2,031.21 USD, and its all-time low was 0.70 USD and was reached on Mar 19, 2020. View more price dynamics on CRDF chart.
See other stocks reaching their highest and lowest prices.
CRDF stock is 10.97% volatile and has beta coefficient of 1.51. Track Cardiff Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cardiff Oncology, Inc. there?
Yes, you can track Cardiff Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Cardiff Oncology, Inc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
CRDF earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.25 USD resulting in a 11.46% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Cardiff Oncology, Inc. earnings.
Cardiff Oncology, Inc. revenue for the last quarter amounts to ‪205.00 K‬ USD, despite the estimated figure of ‪62.50 K‬ USD. In the next quarter, revenue is expected to reach ‪58.75 K‬ USD.
CRDF net income for the last quarter is ‪−10.01 M‬ USD, while the quarter before that showed ‪−9.34 M‬ USD of net income which accounts for −7.22% change. Track more Cardiff Oncology, Inc. financial stats to get the full picture.
No, CRDF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 13, 2024, the company has 32.00 employees. See our rating of the largest employees — is Cardiff Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cardiff Oncology, Inc. EBITDA is ‪−43.88 M‬ USD, and current EBITDA margin is ‪−9.22 K‬%. See more stats in Cardiff Oncology, Inc. financial statements.
Like other stocks, CRDF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cardiff Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cardiff Oncology, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cardiff Oncology, Inc. stock shows the sell signal. See more of Cardiff Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.